Bernd Hentsch
Director/Board Member bij G2M Cancer Drugs AG
Profiel
Bernd Hentsch is currently a Director at G2M Cancer Drugs AG since 2001.
He was previously a Chief Development Officer at 4SC AG and TopoTarget UK Ltd.
Dr. Hentsch holds a doctorate degree from Julius-Maximilians-Universität Würzburg.
Actieve functies van Bernd Hentsch
| Bedrijven | Functie | Begin |
|---|---|---|
G2M Cancer Drugs AG
 G2M Cancer Drugs AG Miscellaneous Commercial ServicesCommercial Services Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The private company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005. | Director/Board Member | 01-01-2001 |
Eerdere bekende functies van Bernd Hentsch
| Bedrijven | Functie | Einde |
|---|---|---|
| 4SC AG | Corporate Officer/Principal | - |
TopoTarget UK Ltd.
 TopoTarget UK Ltd. Drugstore ChainsRetail Trade TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | - |
Opleiding van Bernd Hentsch
| Julius-Maximilians-Universität Würzburg | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| 4SC AG | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
G2M Cancer Drugs AG
G2M Cancer Drugs AG Miscellaneous Commercial ServicesCommercial Services Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The private company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005. | Commercial Services |
TopoTarget UK Ltd.
TopoTarget UK Ltd. Drugstore ChainsRetail Trade TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom. | Retail Trade |
